Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lack of complement activation by human IgA immune complexes.

H Imai1, A Chen, R J Wyatt

  • 1Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, Houston.

Clinical and Experimental Immunology
|September 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of a Charmed Baryon Decaying to D;{0}p at a Mass Near 2.94 GeV/c;{2}.

Physical review letters·2007
Same author

Observation of CP violation in B --> eta'K0 decays.

Physical review letters·2007
Same author

Observation of time-dependent CP violation in B0 --> eta'K0 decays and improved measurements of CP asymmetries in B0 --> phiK0, KS0KS0KS0 and B0 --> J/psiK0 decays.

Physical review letters·2007
Same author

Vector-tensor and vector-vector decay amplitude analysis of B0-->phiK*0.

Physical review letters·2007
Same author

Observation of B-->eta'K* and evidence for B+-->eta'rho+.

Physical review letters·2007
Same author

Measurement of the CP asymmetry and branching fraction of B0-->rho0K0.

Physical review letters·2007
Same journal

Could we discuss the molecular signature of immune dysregulation?

Clinical and experimental immunology·2026
Same journal

The many faces of cytokine storm syndrome: immunopathogenic mechanisms and clinical implications for a better patient management.

Clinical and experimental immunology·2026
Same journal

PD-1 Engagement and Circulating Th17 Effector Activity During Secukinumab Treatment in Plaque Psoriasis.

Clinical and experimental immunology·2026
Same journal

Henoch-Schoenlein purpura (HSP) like lesions in IL12RB1 and IL12B defects - A multi-centric experience from India.

Clinical and experimental immunology·2026
Same journal

Case Series on the Efficacy of Daratumumab in Treating Patients with Anti-Interferon-Gamma Autoantibodies.

Clinical and experimental immunology·2026
Same journal

Deleterious germline CARD11 gain-of-function variants alter human B-cell and CD4+ T-cell differentiation and function.

Clinical and experimental immunology·2026
See all related articles

Human immunoglobulin A (IgA) immune complexes do not activate the complement system, even when deposited in the kidneys. This finding suggests IgA deposits alone may not cause kidney injury via complement pathways.

Area of Science:

  • Immunology
  • Nephrology
  • Complement System Biology

Background:

  • Glomerular deposition of immunoglobulin A (IgA) immune complexes is implicated in renal injury.
  • The role of IgA immune complexes in activating the complement system, a key immune pathway, is not fully understood.

Purpose of the Study:

  • To investigate the in vitro and in vivo complement-activating potential of human IgA immune complexes (IgA-IC) and covalently cross-linked IgA oligomers (X-IgA).
  • To determine if soluble or kidney-localized IgA complexes trigger complement activation, specifically C3 consumption.

Main Methods:

  • Isolation of large-sized IgA-IC from patient serum using affinity purification and gel chromatography.
  • Preparation of stable X-IgA via chemical cross-linking.
  • In vitro complement activation assays using normal human serum, measuring C3 consumption and factor B cleavage.

Related Experiment Videos

  • In vivo studies involving administration of IgA-IC or X-IgA to mice, followed by assessment of glomerular IgA and C3 deposition.

    • Main Results:

    • Neither IgA-IC nor X-IgA induced C3 consumption or factor B cleavage in normal human serum in vitro.
    • Administration of IgA-IC or X-IgA to mice led to significant glomerular IgA deposition.
    • Despite intense glomerular IgA deposits, no C3 was detected in the kidneys of treated mice.

    Conclusions:

    • Soluble human IgA complexes do not activate the complement system.
    • Renal-localized human IgA deposits do not appear to activate complement.
    • These findings suggest that IgA immune complexes may not contribute to renal injury through complement activation.